ALNY vs RMAX · P/E 76, rev $1.29B vs P/E 480, rev $138.7M
Alnylam Pharmaceuticals Inc (ALNY) versus Re Max Holding (RMAX) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Re Max Holding (RMAX) is a real estate services company listed on NYSE.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported RMAX revenue for 2026-06-30 was $138.7M. Net income was -$14.0M. Revenue was up 97.6% from 2026-03-31 to 2026-06-30. RMAX currently screens at market cap $527.7M and trailing P/E 479.5.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. RMAX currently screens at market cap $527.7M and trailing P/E 479.5.
Not investment advice. Open the ALNY and RMAX stock pages for the full models.
Not investment advice.